Fiztasovimab

Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV) . Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV[1].

Product Specifications

CAS Number

[2467411-25-0]

Product Name Alternative

NPC-21; EV2038

UNSPSC

12352203

Target

CMV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/fiztasovimab.html

Purity

96.49

Solubility

10 mM in DMSO

Smiles

[Fiztasovimab]

Molecular Weight

(144.49 kDa)

References & Citations

[1]Furihata K, et al. Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2022 Jun;11 (6) :707-716.